{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:33:11Z","timestamp":1793507591543,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["648131"],"award-info":[{"award-number":["648131"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["847770"],"award-info":[{"award-number":["847770"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"Deutsches Zentrum f\u00fcr Herz-Kreislaufforschung","doi-asserted-by":"publisher","award":["81Z1710103"],"award-info":[{"award-number":["81Z1710103"]}],"id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"Deutsches Zentrum f\u00fcr Herz-Kreislaufforschung","doi-asserted-by":"publisher","award":["81Z0710114"],"award-info":[{"award-number":["81Z0710114"]}],"id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005971","name":"Deutsche Herzstiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005971","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jtha.2025.11.016","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T07:15:41Z","timestamp":1765782941000},"page":"1469-1481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of direct oral anticoagulants on target lesion revascularization rates in patients with chronic coronary syndrome"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7880-0800","authenticated-orcid":false,"given":"Christof","family":"Skos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovan","family":"Rogozarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Postula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceren","family":"Eyileten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate B.","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta M.","family":"Siller-Matula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.11.016_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2009.03.044","article-title":"Combining antiplatelet and anticoagulant therapies","volume":"54","author":"Holmes","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"2 Suppl","key":"10.1016\/j.jtha.2025.11.016_bib2","doi-asserted-by":"crossref","first-page":"e89S","DOI":"10.1378\/chest.11-2293","article-title":"Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Eikelboom","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.11.016_bib3","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1182\/blood-2007-10-120543","article-title":"Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents","volume":"111","author":"Crowther","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.016_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022478","article-title":"Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events\u2014European Registry in Atrial Fibrillation (PREFER in AF)","volume":"9","author":"Rohla","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtha.2025.11.016_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2021.106858","article-title":"Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: a meta-analysis","volume":"138","author":"Gelbenegger","year":"2021","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.jtha.2025.11.016_bib6","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Sch\u00f6mig","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.016_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJM199101033240103","article-title":"Angiographic follow-up after placement of a self-expanding coronary-artery stent","volume":"324","author":"Serruys","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.016_bib8","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.11.016_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.11.016_bib10","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Writing Committee Members","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.11.016_bib11","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/01.CIR.91.6.1676","article-title":"Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance","volume":"91","author":"Colombo","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.11.016_bib12","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.11.016_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1320001","article-title":"Safety and efficacy of NOAC vs. VKA in patients treated by PCI: a retrospective study of the FRANCE PCI registry","volume":"10","author":"Durand","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jtha.2025.11.016_bib14","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/jcm9041120","article-title":"Non-vitamin K oral anticoagulants (NOAC) versus vitamin K antagonists (VKA) for atrial fibrillation with elective or urgent percutaneous coronary intervention: a meta-analysis with a particular focus on combination type","volume":"9","author":"Eyileten","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2025.11.016_bib15","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.amjmed.2018.12.036","article-title":"Net clinical benefit of non-vitamin K antagonist vs vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation","volume":"132","author":"Patti","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2025.11.016_bib16","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.016_bib17","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.11.016_bib18","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/432080","article-title":"Evaluation of plaque stability of advanced atherosclerotic lesions in Apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban","volume":"2011","author":"Zhou","year":"2011","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jtha.2025.11.016_bib19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1160\/th14-03-0268","article-title":"Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis","volume":"112","author":"Schurgers","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.016_bib20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41569-019-0314-y","article-title":"Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease","volume":"17","author":"Capodanno","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jtha.2025.11.016_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1160\/TH13-09-0730","article-title":"Targeting factor Xa and thrombin: impact on coagulation and beyond","volume":"111","author":"Esmon","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.016_bib22","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1093\/eurheartj\/ehv205","article-title":"Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment","volume":"36","author":"Otsuka","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.11.016_bib23","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.11.016_bib24","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1161\/01.CIR.89.3.1262","article-title":"Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits","volume":"89","author":"Ragosta","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.11.016_bib25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cvr\/cvt343","article-title":"Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants","volume":"101","author":"Spronk","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jtha.2025.11.016_bib26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature11701","article-title":"High-resolution crystal structure of human protease-activated receptor 1","volume":"492","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2025.11.016_bib27","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.3390\/ijms20225629","article-title":"Using PAR4 inhibition as an anti-thrombotic approach: why, how, and when?","volume":"20","author":"Li","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtha.2025.11.016_bib28","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.016_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrcardio.2017.206","article-title":"Current and future antiplatelet therapies: emphasis on preserving haemostasis","volume":"15","author":"McFadyen","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jtha.2025.11.016_bib30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.tips.2017.05.001","article-title":"Targeting PAR1: now what?","volume":"38","author":"Flaumenhaft","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jtha.2025.11.016_bib31","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1055\/s-0038-1655767","article-title":"Inhibition of protease-activated receptor (PAR1) reduces activation of the endothelium, coagulation, fibrinolysis and inflammation during human endotoxemia","volume":"118","author":"Schoergenhofer","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.016_bib32","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/35025229","article-title":"Thrombin signalling and protease-activated receptors","volume":"407","author":"Coughlin","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2025.11.016_bib33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41573-020-0061-0","article-title":"Therapeutic strategies for thrombosis: new targets and approaches","volume":"19","author":"Mackman","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtha.2025.11.016_bib34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41569-023-00854-6","article-title":"Current concepts and novel targets for antiplatelet therapy","volume":"20","author":"Gawaz","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jtha.2025.11.016_bib35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12959-019-0194-8","article-title":"Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases","volume":"17","author":"Heuberger","year":"2019","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2025.11.016_bib36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/hh1301.092661","article-title":"Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists","volume":"89","author":"Hamilton","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.jtha.2025.11.016_bib37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00281-011-0289-1","article-title":"Protease-activated receptor 2 signaling in inflammation","volume":"34","author":"Rothmeier","year":"2012","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jtha.2025.11.016_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123157","article-title":"Factor XI inhibitors\u2014rising stars in anti-thrombotic therapy?","volume":"464","author":"Nolte","year":"2024","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jtha.2025.11.016_bib39","doi-asserted-by":"crossref","first-page":"C377","DOI":"10.1152\/ajpcell.00426.2018","article-title":"Coagulation factor XI induces Ca2+ response and accelerates cell migration in vascular smooth muscle cells via proteinase-activated receptor 1","volume":"316","author":"Liu","year":"2019","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jtha.2025.11.016_bib40","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.016_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.016_bib42","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.016_bib43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/heartjnl-2019-315090","article-title":"Pharmacology before, during and after percutaneous coronary intervention","volume":"107","author":"Zaman","year":"2021","journal-title":"Heart"},{"key":"10.1016\/j.jtha.2025.11.016_bib44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.120.046048","article-title":"The COMPASS trial","volume":"142","author":"Steffel","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.11.016_bib45","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/ehjcvp\/pvab043","article-title":"Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials","volume":"8","author":"Galli","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jtha.2025.11.016_bib46","doi-asserted-by":"crossref","first-page":"e01","DOI":"10.15420\/ecr.2023.40","article-title":"Dual-pathway inhibition with low-dose aspirin and rivaroxaban versus aspirin monotherapy in patients with coronary artery disease and peripheral artery disease: systematic literature review and meta-analysis","volume":"19","author":"Sibbing","year":"2024","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.jtha.2025.11.016_bib47","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMoa2507532","article-title":"Aspirin in patients with chronic coronary syndrome receiving oral anticoagulation","volume":"393","author":"Lemesle","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.016_bib48","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.11.016_bib49","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/eurheartj\/ehab785","article-title":"Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score","volume":"43","author":"W\u00fcrtz","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625008967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625008967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:17:06Z","timestamp":1781939826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625008967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1538783625008967"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.11.016","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of direct oral anticoagulants on target lesion revascularization rates in patients with chronic coronary syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}